Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2000 Mar;68(3):353–357. doi: 10.1136/jnnp.68.3.353

Evaluation of 18fluorodeoxyglucose positron emission tomography (18FDG PET) in the detection of malignant peripheral nerve sheath tumours arising from within plexiform neurofibromas in neurofibromatosis 1

R Ferner 1, J Lucas 1, M O'Doherty 1, R Hughes 1, M Smith 1, B Cronin 1, J Bingham 1
PMCID: PMC1736834  PMID: 10675220

Abstract

OBJECTIVES—The ability of 18fluorodeoxyglucose positron emission tomography (18FDG PET) to detect malignant change in plexiform neurofibromas from patients with neurofibromatosis 1 (NF1) was evaluated.
METHODS—Eighteen NF1 patients who presented with pain, increase in size, or neurological deficit associated with a plexiform neurofibroma were assessed. Magnetic resonance imaging determined the site and extent of the lesion. Qualitative18FDG PET was performed and the standard uptake value (SUV) measured the regional glucose metabolism. Histological confirmation of the diagnosis was obtained in 10patients.
RESULTS—Twenty three plexiform neurofibromas were detected in 18 patients. Seven malignant peripheral nerve sheath tumours, four high grade and three low grade tumours, occurred in five patients. In one patient the clinical and radiological characteristics of the tumour suggested malignancy, but histology was inconclusive. Fifteen benign plexiform neurofibromas were identified in 12 patients and these findings were confirmed histologically in five lesions from four patients. Ten plexiform neurofibromas occurring in eight patients were considered benign on18FDG PET and the patients did not undergo surgery. They remained stable or their symptoms improved on clinical follow up (median 9 months). The results of qualitative 18FDG PET were interpreted as indicating that 13 plexiform neurofibromas were benign and 10 were malignant. No malignant tumours were classified as benign, but two benign tumours were reported as malignant. The SUV was calculated for 20 tumours and was significantly higher in five malignant tumours 5.4 (SD 2.4), than in 15 benign tumours 1.54 (SD 0.7), p=0.002. There was an overlap between benign and malignant tumours in the SUV range 2.7-3.3.
CONCLUSIONS—18FDG PET is helpful in determining malignant change in plexiform neurofibromas in NF1. Increased separation between benign and malignant lesions could be obtained by calculating the SUV at about 200 minutes after injection of 18FDG, when the peak activity concentration is obtained in malignant tumours.



Full Text

The Full Text of this article is available as a PDF (135.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler L. P., Blair H. F., Makley J. T., Williams R. P., Joyce M. J., Leisure G., al-Kaisi N., Miraldi F. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med. 1991 Aug;32(8):1508–1512. [PubMed] [Google Scholar]
  2. Ducatman B. S., Scheithauer B. W., Piepgras D. G., Reiman H. M., Ilstrup D. M. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986 May 15;57(10):2006–2021. doi: 10.1002/1097-0142(19860515)57:10<2006::aid-cncr2820571022>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  3. Eary J. F., Mankoff D. A. Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med. 1998 Feb;39(2):250–254. [PubMed] [Google Scholar]
  4. Griffeth L. K., Dehdashti F., McGuire A. H., McGuire D. J., Perry D. J., Moerlein S. M., Siegel B. A. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology. 1992 Jan;182(1):185–194. doi: 10.1148/radiology.182.1.1727280. [DOI] [PubMed] [Google Scholar]
  5. Hermann G., Abdelwahab I. F., Miller T. T., Klein M. J., Lewis M. M. Tumour and tumour-like conditions of the soft tissue: magnetic resonance imaging features differentiating benign from malignant masses. Br J Radiol. 1992 Jan;65(769):14–20. doi: 10.1259/0007-1285-65-769-14. [DOI] [PubMed] [Google Scholar]
  6. Huson S. M., Harper P. S., Compston D. A. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain. 1988 Dec;111(Pt 6):1355–1381. doi: 10.1093/brain/111.6.1355. [DOI] [PubMed] [Google Scholar]
  7. Kern K. A., Brunetti A., Norton J. A., Chang A. E., Malawer M., Lack E., Finn R. D., Rosenberg S. A., Larson S. M. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med. 1988 Feb;29(2):181–186. [PubMed] [Google Scholar]
  8. Lawrence W., Jr, Donegan W. L., Natarajan N., Mettlin C., Beart R., Winchester D. Adult soft tissue sarcomas. A pattern of care survey of the American College of Surgeons. Ann Surg. 1987 Apr;205(4):349–359. doi: 10.1097/00000658-198704000-00003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lodge M. A., Lucas J. D., Marsden P. K., Cronin B. F., O'Doherty M. J., Smith M. A. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med. 1999 Jan;26(1):22–30. doi: 10.1007/s002590050355. [DOI] [PubMed] [Google Scholar]
  10. Lucas J. D., O'Doherty M. J., Wong J. C., Bingham J. B., McKee P. H., Fletcher C. D., Smith M. A. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas. J Bone Joint Surg Br. 1998 May;80(3):441–447. doi: 10.1302/0301-620x.80b3.8232. [DOI] [PubMed] [Google Scholar]
  11. Nieweg O. E., Pruim J., van Ginkel R. J., Hoekstra H. J., Paans A. M., Molenaar W. M., Koops H. S., Vaalburg W. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996 Feb;37(2):257–261. [PubMed] [Google Scholar]
  12. Strauss L. G., Conti P. S. The applications of PET in clinical oncology. J Nucl Med. 1991 Apr;32(4):623–650. [PubMed] [Google Scholar]
  13. Tonsgard J. H., Kwak S. M., Short M. P., Dachman A. H. CT imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform lesions. Neurology. 1998 Jun;50(6):1755–1760. doi: 10.1212/wnl.50.6.1755. [DOI] [PubMed] [Google Scholar]
  14. Trojani M., Contesso G., Coindre J. M., Rouesse J., Bui N. B., de Mascarel A., Goussot J. F., David M., Bonichon F., Lagarde C. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984 Jan 15;33(1):37–42. doi: 10.1002/ijc.2910330108. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES